Source: Eur Respir J, 54 (1) 1900439; 10.1183/13993003.00439-2019
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Alyn H. Morice, Michael M. Kitt, Anthony P. Ford, Andrew M. Tershakovec, Wen-Chi Wu, Kayleigh Brindle, Rachel Thompson, Susannah Thackray-Nocera, Caroline Wright. The effect of gefapixant, a P2X3 antagonist, on cough reflex sensitivity: a randomised placebo-controlled study. Eur Respir J, 54 (1) 1900439; 10.1183/13993003.00439-2019

Member's Comments

No comment yet.

Related content which might interest you: Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study Source: Eur Respir J, 58 (5) 2004240; 10.1183/13993003.04240-2020 Year: 2021 Late Breaking Abstract - Phase 2a randomised, double-blind, placebo-controlled, crossover study of a novel P2X3 receptor antagonist S-600918 in patients with refractory chronic cough Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: COPD and cough Year: 2019 Design of phase 2b randomised controlled trial of S-600918, P2X3 receptor antagonist for refractory chronic cough Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020 A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis Source: Eur Respir J 2015; 46: 1021-1032 Year: 2015 Efficacy and safety of revefenacin (REV), a long-acting muscarinic antagonist for nebulization: results of replicate randomized, double-blind, placebo-controlled, parallel-group phase 3 trials in participants with moderate to very severe COPD Source: International Congress 2017 – Bronchodilators and bronchoprotectors Year: 2017 Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough Source: ERJ Open Res, 6 (4) 00284-2020; 10.1183/23120541.00284-2020 Year: 2020 LATE-BREAKING ABSTRACT: A randomised, double-blind, placebo-controlled study of the CRTH2 antagonist OC000459 on moderate persistent asthma Source: Annual Congress 2009 - Novel approaches in asthma Year: 2009 Inhibition of P2X3 by MK-7264 reduces 24-hour cough frequency in a randomized, controlled, Phase 2b clinical trial Source: International Congress 2017 – New ideas for the management of chronic lung diseases Year: 2017 Characterization of chronic cough patients participating in a phase 2b clinical trial of gefapixant, a P2X3 receptor antagonist Source: International Congress 2019 – Highlights in lung function and chronic cough Year: 2019 Late-breaking abstract: Inhaled pan-selectin antagonist bimosiamose in COPD: A double-blind, randomized, placebo-controlled phase II study Source: Annual Congress 2011 - Late-Breaking Abstracts Session: New treatments and targets for airway disease Year: 2011 Baseline patient burden in chronic cough from a Phase 2b clinical trial of gefapixant, a P2X3 receptor antagonist Source: International Congress 2019 – Highlights in lung function and chronic cough Year: 2019 Impact of oral clonidine on duration of opioid and benzodiazepine use in mechanically ventilated children: a randomized, double-blind, placebo-controlled study Source: Virtual Congress 2020 – Neonatal and paediatric intensive care: diagnosis, management and outcomes Year: 2020 Detrimental effects of β-blockers in COPD: a concern for nonselective β-blockers: a randomised, placebo controlled, cross-over study Source: Eur Respir J 2003; 22: Suppl. 45, 49s Year: 2003 Omalizumab efficacy following cat allergen exposure: Results from a randomized, double-blind, placebo-controlled, parallel-group study in patients with moderate asthma Source: Annual Congress 2010 - Asthma: clinical aspects and treatment Year: 2010 An open-label pilot study of memantine, an N-methyl-D-aspartate receptor antagonist in chronic cough Source: International Congress 2014 – Novel evidence relating to respiratory treatment development Year: 2014 A randomised placebo controlled trial to evaluate the effects of butamirate and dextromethorphan on capsaicin induced cough in healthy volunteers Source: Annual Congress 2013 –Novel drugs and biomarkers in respiratory medicine Year: 2013 A randomised, double-blind study to determine the duration of action of lung pharmacodynamics by plethysmography (sGaw) of a b2 adrenoreceptor agonist, PF-00610355 Source: Annual Congress 2009 - New bronchodilators Year: 2009 A randomized, double-blind, placebo-controlled study to evaluate the role of formoterol in management of acute asthma Source: Eur Respir J 2006; 28: Suppl. 50, 498s Year: 2006 Short-term effect of a single dose of inhaled procaterol on exercise performance in COPD: a randomized, double blind, placebo-controlled, crossover trial Source: Annual Congress 2008 - Physiological response to exercise performance Year: 2008 Acetazolamide administration following upper airway surgery for SDB. Preliminary results of a randomized, double-blind, placebo-controlled study Source: Eur Respir J 2005; 26: Suppl. 49, 201s Year: 2005